Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
In this program, a panel of retina specialists share their insights into the use of newer anti-VEGF agents, which offer the opportunity for extended treatment intervals for the treatment of retinal vein occlusion (RVO), neovascular age-related macular degeneration, and diabetic macular edema. Featured in the program are discussions of recently presented data for these therapies, illustrative cases, and suggestions regarding ways to improve the comanagement of these diseases between retina specialists, optometrists, and general ophthalmologists.
Target Audience
These educational activities are directed toward optometrists, ophthalmologists, and other health care professionals involved in the management of patients with neovascular retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize the clinical features of RVO using advanced imaging techniques.
- Define appropriate referral efficiency and comanagement between optometrists and retina specialists in the management of nAMD.
- Evaluate the latest clinical trial data on next-generation anti-VEGF therapies and their implications for extended dosing intervals in nAMD management.
- Classify effective patient communication strategies to address concerns about intravitreal therapy and optimize treatment adherence for patients with DME.
Dilsher Dhoot, MD, FASRS
Adjunct Clinical Assistant Professor of Ophthalmology
Keck School of Medicine, USC
California Retina Consultants
Santa Barbara, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bayer Healthcare Pharmaceuticals, Inc; BioCryst; Coherus Oncology; EyePoint Pharmaceuticals; Genentech; Iveric Bio; Novartis; Ocular Therapeutix; Oculis, Optos, Inc; Outlook Therapeutics; Oxular; Regeneron; RegenXbio; RetinAI, Roche; Santen, Inc. Grant/Research Funding: 4DMT; Adverum Biotechnologies; Apellis Pharmaceuticals; EyePoint Pharmaceuticals; Genentech; Ocular Therapeutix; Regeneron; RegenXbio
Jordana G. Fein, MD, MS
Assistant Professor of Ophthalmology
Georgetown University School of Medicine
Retina Group of Washington
Fairfax, VA
Disclosures: Grant/Research Support: 4DMT; Alexion; Apellis Pharmaceuticals; Bayer; ForeseeHome; Kyowa Kirin; Ocular Therapeutix; Regeneron. Advisor/Consultant/Speaker/Honoraria Recipient: Apellis Pharmaceuticals; Bayer; EyePoint Pharmaceuticals; Genentech; Regeneron; Roche Ownership Interests in publicly traded companies: EyePoint Pharmaceuticals
Deep Parikh, MD
Ophthalmologist
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Consultant: Alimera Sciences, Zeiss
Xiao-Yi (Ellie) Zhou, MD
Assistant Professor of Ophthalmology
and Visual Science
Assistant Professor of Pathology
The University of Chicago Medicine
Chicago, IL
Xiao-Yi (Ellie) Zhou, MD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, has no relevant financial relationships with ineligible companies.
PER mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here